7-chloro-3-(2,4-dichlorophenyl)-5-methylpyrazolo[4,3-b]pyridine | 268547-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-chloro-3-(2,4-dichlorophenyl)-5-methylpyrazolo[4,3-b]pyridine
• 英文别名: 7-chloro-3-(2,4-dichlorophenyl)-5-methyl-2H-pyrazolo[4,3-b]pyridine
• CAS: 268547-49-5
• 化学式: C₁₃H₈Cl₃N₃
• 分子量: 312.586
• InChiKey: SKIAJUFEBOQMTK-UHFFFAOYSA-N

物化性质

• 熔点：
  240 °C
• 沸点：
  464.9±40.0 °C(Predicted)
• 密度：
  1.519±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-chloro-3-(2,4-dichlorophenyl)-5-methylpyrazolo[4,3-b]pyridine 在 2-甲基苯磺酸 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 Dibutyl-[3-(2,4-dichloro-phenyl)-1-ethyl-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-amine
  参考文献：
  名称：

  Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-Releasing factor receptor type-1 antagonists

  摘要：

  3-Phenylpyrazolo[4,3-b]pyridines were synthesized via a cyclization of 4-amino-3-phenylpyrazoles 11-13 with ethyl acetoacetate. These compounds were found to be potent CRF1 antagonists. The 2-alkylpyrazolo[4,3-b]pyridines were more polar but less active than the corresponding 1-alkyl-isomers. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00621-8
• 作为产物：
  描述：

  2,2',4'-三氯苯乙酮 在 盐酸肼 、 对甲苯磺酸 、 一水合肼 、 N,N-二甲基甲酰胺 、 三氯氧磷 作用下， 以 二苯醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 28.5h， 生成 7-chloro-3-(2,4-dichlorophenyl)-5-methylpyrazolo[4,3-b]pyridine
  参考文献：
  名称：

  Design and Synthesis of Tricyclic Corticotropin-Releasing Factor-1 Antagonists

  摘要：

  Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochemical properties, new tricyclic CRF, antagonists were designed, synthesized, and tested for biological activity. As a result of studies aimed at establishing a relationship between structure and CRF, binding affinity, NBI 35965 (12a) was identified as a high-affinity antagonist with a pK(i) value of 8.5. Compound 12a proved to be a functional CRF, antagonist with pIC(50) values of 7.1 and 6.9 in the in vitro CRF-stimulated cAMP accumulation and ACTH production assays, respectively, and 12a also reduced CRF or stress induced ACTH production in vivo.

  DOI：

  10.1021/jm049085v

文献信息

• CRF receptor antagonists and methods relating thereto
  申请人：Neurocrine Biosciences, Inc.

  公开号：US06514982B1

  公开（公告）日：2003-02-04

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2 and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same

  本发明揭示了CRF受体拮抗剂，其在治疗多种疾病方面具有用途，包括治疗温血动物中CRF分泌过多表现的疾病，例如中风。本发明的CRF受体拮抗剂具有以下结构：包括立体异构体和其药学上可接受的盐，其中n、m、A、B、C、R、R1、R2和Ar的定义如本文所述。本发明还揭示了含有CRF受体拮抗剂和药学上可接受的载体组合的组合物，以及使用它们的方法。